·Î°©ÊÇ·¢²¡ÂÊ×î¸ßµÄÖ×Áö£¬Ñо¿±íÃ÷£¬·Î°©µÄÔçÆÚɸ²éºÍÕï¶ÏÄܹ»¼«´óµÄÌá¸ßÎåÄêÉú´æÂÊ¡£Cancers(Basel)·¢±íһƪÌâΪNon-Invasive Biomarkers for Early Lung Cancer DetectionµÄ×ÛÊö£¬È«Ãæ½éÉÜÁ˷ΰ©ÔçɸÉúÎï±êÖ¾ÎïµÄÑо¿½øÕ¹¡£
±¾Æª×ÛÊöÊ×ÏÈÌá³ö£¬ÀíÏëµÄÖ×ÁöÉúÎï±êÖ¾ÎïÓ¦¸Ã¾ßÓÐÒÔÏÂÌØÕ÷£º
(1) Äþ¾²¡¢Ò×ÓÚÊÕÂ޺ͼì²â£¬¾ßÓгɱ¾Ð§Ò棻
(2) ²»ÊÜÐÔ±ð»òÖÖ×åµÈÖØÒªÈË¿Úͳ¼ÆÊý¾ÝµÄÓ°Ï죻
(3) ¸ßÁéÃô¶È¿É׼ȷ·¢ÏÖÔçÆÚ°©Ö¢£»
(4) ×îÉÙµÄÈËÁ¦Í¶Èë£¬ÌØ±ðÊÇ´óÁ¿Êý¾ÝµÄ·ÖÎö£¬ÒÔ¼õÉÙ¶ÔÈËÁ¦×ÊÔ´µÄÓ°Ïì¡£
Ðí¶à·ÇÇÖÈëÐÔÉúÎï±êÖ¾ÎÈçctDNA¡¢CTC¡¢ÂѰ×ÖÊ¡¢Ö¬ÖÊ¡¢RNAºÍmicroRNA£¨miRNA£©£¬¿ÉÒÔÔÚѪ½¬¡¢ÑªÇå¡¢ÄòÒº¡¢ÍÙÒº¡¢¸¹Ë®ºÍÄÔ¼¹ÒºµÈÌåÒºÖмì²âµ½¡£ÕâЩÉúÎï±êÖ¾Îï±»¹ã·ºÑо¿£¬È»¶ø£¬ÓÉÓÚ»ùÒò×éµÄ²»Îȶ¨ÐÔ£¬ÒÔ¼°·Î°©Ï¸°ûµÄÁ¬ÐøÑݱ䣬ÉúÎï±êÖ¾ÎïµÄ±í´ï»áÓкܴóµÄ±ä»¯£¬ÀíÏëµÄÉúÎï±êÖ¾ÎïÉÐδ·¢ÏÖ¡£
DNA¼×»ù»¯
·Î°©±í¹ÛÒÅ´«±ä»¯Êdz£¼ûµÄ£¬Ñª½¬ÖÐDNA¼×»ù»¯µÄ¼ì²â£¬×÷Ϊɸ²éºÍÕï¶Ï·Î°©µÄ°×±êÖ¾ÎҲÏÔʾ³öǰ¾°¡£BearzattoµÈÈ˱¨µÀÁËp16INK4A¼×»ù»¯ÔÚÔçÆÚÏÙ°©Ñª½¬Ñù±¾ÖÐÆµÂÊÔö¼Ó¡£Í¬Ñù£¬ÑªÒºÑù±¾Öмì²âµ½µÄRASSF1AºÍCDKN2A¼×»ù»¯ÔÚÔçÆÚ·Î°©Öо³£±»·¢ÏÖ£¬¾Ý±¨µÀÃô¸ÐÐÔΪ22%ÖÁ66%£¬ÌØÒìÐÔΪ57-100%¡£
microRNA(miRNA)
miRNAÊdz¤¶ÈΪ18-25¸öºËÜÕËáµÄСÐͷDZàÂëRNA£¬¼ÓÈë»ùÒò±í´ïת¼ºóµ÷¿Ø¡£ËüÃÇÔÚ°üÂÞ°©Ö¢ÔÚÄÚµÄÐí¶à²¡ÀíÌõ¼þÏÂÒì³£±í´ï£¬¶øÇÒ¿ÉÒÔÔÚÄòÒº¡¢ÌµÒººÍѪҺÖмì²âµ½£¬Ê¹ËüÃdzÉΪ°©Ö¢¼ì²âµÄÉúÎï±êÖ¾Îï¡£miRNA¿ÉÒÔ×÷ΪÖ×ÁöÒÖÖÆÒò×Ó»ò°©»ùÒò£¬ÉõÖÁÁ½Õß¼æ¶øÓÐÖ®¡£´ËÍ⣬miRNAÔÚ°©Ö¢·¢ÉúÉú³¤µÄÕû¸ö¹ý³ÌÖб£³ÖÎȶ¨ÐÔ£¬ÒòΪËüÃÇ̫С¶øÎÞ·¨½µ½â£¬¶øÇÒһЩmiRNAÔÚÍâÃÚÌåÖнøÒ»²½Êܵ½±£»¤¡£Òò´Ë£¬miRNA±»ÈÏΪÊǰ©Ö¢Õï¶ÏºÍ¼à²âµÄÒ»¸öÓÐÎüÒýÁ¦µÄÉúÎï±êÖ¾Îï¡£
ÔÚYanaiharaµÈÈ˵ÄÔçÆÚÑо¿ÖУ¬miR-17-3p¡¢miR-21¡¢miR-106a¡¢miR-146¡¢miR-155¡¢miR-191¡¢miR-192¡¢miR-203¡¢miR-205¡¢miR-210¡¢miR-212ºÍmiR-214µÈ12ÖÖmicroRNAÔÚ²îÒìµÄ¶ñÐÔ×éÖ¯Öбí´ï²îÒ죬±»¼ø¶¨ÎªÇø·Ö·Î°©ºÍÁ¼ÐÔ·Î×éÖ¯µÄDZÔÚÉúÎï±êÖ¾Îï¡£WozniakµÈÈ˵ÄÁíÒ»ÏîÑо¿±íÃ÷£¬24ÖÖmiRNAµÄ×éºÏÄܹ»½«·Î°©²¡ÀýÓ뽡¿µ¶ÔÕÕÇøÀ뿪À´¡£×÷ÕßÈÏΪ£¬ÉÏÊömiRNAÔÚѪ½¬ÖеĹý±í´ï¿É×÷ΪÔçÆÚ¼ì²âNSCLCµÄÉúÎï±êÖ¾ÎֵµÃ½øÒ»²½Ñо¿¡£
ctDNA
ctDNA£¨Ñ»·Ö×ÁöDNA£©°üÂÞѪҺ»òÆäËûÌåÒºÖб»°ü¹üµÄ£¨ÔÚÑ»·ÄÒÅÝÖУ©ºÍδ±»°ü¹üµÄÓÎÀëDNA£¬ctDNAÊÇÒ»ÖÖºÜÓÐǰ;µÄÉúÎï±êÖ¾Îï¡£
ͼ1 ctDNAºÍ×éÖ¯»î¼ìµÄÖØÒªÇø±ð
×îºó£¬±¾Æª×ÛÊöÖ¸³öĿǰ¿ª·¢ÓÐЧºÍ¿É¿¿µÄÖ×ÁöÉúÎï±êÖ¾Îï´æÔÚµÄÌôÕ½£º
(1) ȱ·¦“ÀíÏëµÄ”ÉúÎï±êÖ¾Îï×÷Ϊ½ð³ß¶È£¬Ê¹µÃÑé֤еÄÉúÎï±êÖ¾ÎïÒÔÓÐЧÕï¶Ï°©Ö¢£¬¼´½¨Á¢ÁÙ´²Ïà¹ØÐÔºÍÊÊÓÃÐÔ¾ßÓÐÌôÕ½ÐÔ¡£
(2) Ö×Áö½ø»¯²»ÐÐÖÆÖ¹µØµ¼ÖÂÍ»±ä¶àÑùÐÔ£¬µ¼ÖÂÖ×Áö¼äºÍÖ×ÁöÄÚµÄÒìÖÊÐÔ£¬´Ó¶øµ¼ÖÂÌØ¶¨Ô·¢Ö×ÁöÖÐÉúÎï±êÖ¾ÎïµÄ±ä»¯¡£
(3) ÉúÎï±êÖ¾ÎïµÄÅÓ´óÐԺͶ¯Ì¬±ä»¯£¨ÌرðÊÇÔÚѪ½¬ÖУ©Ê¹µÃÔÚͬһ»¼ÕßÖлòÔÚ»¼ÕßÖ®¼ä½øÐбÈÁ¦Ê±·Ç³£À§ÄÑ¡£
(4) Ðí¶àÌØÒìÐÔÉúÎï±êÖ¾ÎïµÄÏà¶ÔƷò½ÏµÍ£¬Í¨³£»áµ¼Ö¼ÙÒõÐÔ½á¹û£¬Òò´ËÌØÒìÐԽϵ͡£
(5) ÑùÆ·ÊÕ¼¯¡¢´¢´æ¡¢ÔËÊäºÍ¼¼ÊõÖеıäÁ¿£¬¿ÉÄܵ¼Ö½á¹û·×ÆçÖ£¬¶ÔÉúÎï±êÖ¾ÎïµÄÓÐЧÐԺͿɿ¿ÐÔ·¢Éúµ¹Ã¹Ó°Ïì¡£
(6) ÓëÐÂÒ©¿ª·¢ÃæÁÙµÄÌôÕ½ÀàËÆ£¬°©Ö¢ÐÂÉúÎï±êÖ¾ÎïµÄ¿ª·¢Éæ¼°´ÓʵÑéÊÒµ½ÁÙ´²µÄÅÓ´ó¡¢Âþ³¤ÇÒ°º¹óµÄ·¾¶¡£
²Î¿¼ÎÄÏ×
Cancers (Basel). 2022 Nov 24; 14(23): 5782. doi: 10.3390/cancers14235782.